UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 78

Sortiert nach

Telmisartan in Migraine Prophylaxis: A Randomized, Placebo-Controlled Trial

Cephalalgia, 2009-09, Vol.29 (9), p.921-927

2009

Volltextzugriff (PDF)

Clinical outcomes of hemodialysis patients in a public-private partnership care framework in Italy: a retrospective cohort study

BMC nephrology, 2019-02, Vol.20 (1), p.35-35, Article 35

2019

Volltextzugriff (PDF)

Serum Uric Acid and Mortality Risk Among Hemodialysis Patients

Kidney international reports, 2020-08, Vol.5 (8), p.1196-1206

2020

Volltextzugriff (PDF)

Cancer patients and characteristics of pulmonary embolism

European journal of radiology, 2009-03, Vol.69 (3), p.478-482

2009

Volltextzugriff (PDF)

Short-term sedation of mechanically ventilated ICU patients with propofol, benzodiazepines, or dexmedetomidine: systematic review and meta-analysis on awakening and recovery times

Critical care (London, England), 2015-01, Vol.19 (S1), p.P486-P486, Article P486

2015

Volltextzugriff (PDF)

Development of a screening tool for migraine prophylaxis

Schmerz (Berlin, Germany), 2007-10, Vol.21 (5), p.430-438

2007

Volltextzugriff (PDF)

Propofol or benzodiazepines for short- and long-term sedation in intensive care units? An economic evaluation based on meta-analytic results

ClinicoEconomics and outcomes research, 2017-01, Vol.9, p.685-698

2017

Volltextzugriff (PDF)

Impact of Age, Height, and Body Mass Index on Arterial Diameters in Infants and Children: A Model for Predicting Femoral Artery Diameters Prior to Cardiovascular Procedures

Journal of endovascular therapy, 2004-08, Vol.11 (4), p.419-423

2004

Volltextzugriff (PDF)

Femoral Artery Blood Flow in Infants and Children

Journal for vascular ultrasound, 2005-06, Vol.29 (2), p.75-78

2005

Volltextzugriff (PDF)

Entwicklung eines Migräneprophylaxe-Screeninginstruments (MPS)

Schmerz (Berlin, Germany), 2007-09, Vol.21 (5), p.430-438

2007

Volltextzugriff (PDF)

Factors Associated With Reduced Response to Subcutaneous C1-Inhibitor in Patients With Hereditary Angioedema

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB108

2020

Volltextzugriff (PDF)

Weight-based Dosing of Subcutaneous C1-Inhibitor Facilitates Management of Hereditary Angioedema in Obese Patients

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB106

2020

Volltextzugriff (PDF)

1018 Profiles of medication use in dialysis patients globally

Nephrology, dialysis, transplantation, 2024-05, Vol.39 (Supplement_1)

2024

Volltextzugriff (PDF)

A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab

Clinical and translational science, 2022-03, Vol.15 (3), p.626-637

2022

Volltextzugriff (PDF)

LONG-TERM SAFETY AND EFFICACY WITH GARADACIMAB FOR HEREDITARY ANGIOEDEMA PROPHYLAXIS IN AN OPEN-LABEL EXTENSION STUDY

Annals of allergy, asthma, & immunology, 2023-11, Vol.131 (5), p.S5-S5

2023

Volltextzugriff (PDF)

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

Allergy (Copenhagen), 2015-10, Vol.70 (10), p.1319-1328

2015

Volltextzugriff (PDF)

Garadacimab For Hereditary Angioedema Prophylaxis In Adolescents: Efficacy And Safety From The Phase 3 (VANGUARD) Study And Open-Label Extension (Second Interim Analysis)

Journal of allergy and clinical immunology, 2024-02, Vol.153 (2), p.AB6

2024

Volltextzugriff (PDF)

Effects of high-volume online mixed-hemodiafiltration on anemia management in dialysis patients

PloS one, 2019-02, Vol.14 (2), p.e0212795-e0212795

2019

Volltextzugriff (PDF)

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Intravenous and Subcutaneous Garadacimab (CSL312) in Healthy Subjects

Journal of allergy and clinical immunology, 2021-02, Vol.147 (2), p.AB137-AB137

2021

Volltextzugriff (PDF)

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet (British edition), 2022-03, Vol.399 (10328), p.945-955

2022

Volltextzugriff (PDF)

134 Patterns of On-Demand Medication Use in the Treatment of Hereditary Angioedema Attacks: Implications for the Management of Hereditary Angioedema in the Emergency Department

Annals of emergency medicine, 2018-10, Vol.72 (4), p.S56-S56

2018

Volltextzugriff (PDF)

Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters

Thrombosis and haemostasis, 2021-05, Vol.121 (5), p.690

2021

Volltextzugriff (PDF)

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

The New England journal of medicine, 2017-03, Vol.376 (12), p.1131-1140

2017

Volltextzugriff (PDF)

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-04, Vol.401 (10382), p.1079-1090

2023

Volltextzugriff (PDF)

P160 LONG-TERM PROPHYLAXIS WITH SUBCUTANEOUS C1-INHIBITOR IN US PATIENTS WITH HEREDITARY ANGIOEDEMA AND VERY FREQUENT ATTACKS

Annals of allergy, asthma, & immunology, 2019-11, Vol.123 (5), p.S31-S31

2019

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(74)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(33)
Humans
(23)
Female
(18)
Male
(18)
Angioedema
(14)
Edema
(14)
Adult
(13)
Middle Aged
(12)
Patients
(11)
Allergy
(10)
Treatment Outcome
(10)
Aged
(9)
Allergy And Immunology
(9)
Prophylaxis
(9)
Immunology
(8)
Adolescent
(7)
Angioedemas, Hereditary - Drug Therapy
(7)
Young Adult
(7)
Double-Blind Method
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Telmisartan in Migraine Prophylaxis: A Randomized, Placebo-Controlled Trial

Clinical outcomes of hemodialysis patients in a public-private partnership care framework in Italy: a retrospective cohort study

Serum Uric Acid and Mortality Risk Among Hemodialysis Patients

Cancer patients and characteristics of pulmonary embolism

Short-term sedation of mechanically ventilated ICU patients with propofol, benzodiazepines, or dexmedetomidine: systematic review and meta-analysis on awakening and recovery times

Development of a screening tool for migraine prophylaxis

Propofol or benzodiazepines for short- and long-term sedation in intensive care units? An economic evaluation based on meta-analytic results

Impact of Age, Height, and Body Mass Index on Arterial Diameters in Infants and Children: A Model for Predicting Femoral Artery Diameters Prior to Cardiovascular Procedures

Femoral Artery Blood Flow in Infants and Children

Entwicklung eines Migräneprophylaxe-Screeninginstruments (MPS)

Factors Associated With Reduced Response to Subcutaneous C1-Inhibitor in Patients With Hereditary Angioedema

Weight-based Dosing of Subcutaneous C1-Inhibitor Facilitates Management of Hereditary Angioedema in Obese Patients

1018 Profiles of medication use in dialysis patients globally

A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab

LONG-TERM SAFETY AND EFFICACY WITH GARADACIMAB FOR HEREDITARY ANGIOEDEMA PROPHYLAXIS IN AN OPEN-LABEL EXTENSION STUDY

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

Garadacimab For Hereditary Angioedema Prophylaxis In Adolescents: Efficacy And Safety From The Phase 3 (VANGUARD) Study And Open-Label Extension (Second Interim Analysis)

Effects of high-volume online mixed-hemodiafiltration on anemia management in dialysis patients

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Intravenous and Subcutaneous Garadacimab (CSL312) in Healthy Subjects

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

134 Patterns of On-Demand Medication Use in the Treatment of Hereditary Angioedema Attacks: Implications for the Management of Hereditary Angioedema in the Emergency Department

Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

P160 LONG-TERM PROPHYLAXIS WITH SUBCUTANEOUS C1-INHIBITOR IN US PATIENTS WITH HEREDITARY ANGIOEDEMA AND VERY FREQUENT ATTACKS

Suchergebnisse filtern